| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/31/2001 | WO2001038304A1 Heterocyclic ketone and thioester compounds and uses |
| 05/31/2001 | WO2001038303A2 Vitamin d analogues |
| 05/31/2001 | WO2001038293A1 Ethers of o-desmethyl venlafaxine |
| 05/31/2001 | WO2001038288A1 Nervonic acid derivatives, their preparation and use |
| 05/31/2001 | WO2001037890A1 A propellant free spray-on skin patch composition for improving wound healing and for drug administration |
| 05/31/2001 | WO2001037877A1 Remedies for diseases in association with decrease in bone mass |
| 05/31/2001 | WO2001037876A2 Methods of ameliorating abnormal bone states |
| 05/31/2001 | WO2001037854A1 Method for treatment and prevention of physiological shock |
| 05/31/2001 | WO2001037851A2 Use of ubiquinone q10 for the local treatment and prevention of post-surgical ophthalmologic pathologies |
| 05/31/2001 | WO2001037846A1 Method and composition for the treatment of adenoviral ocular infections |
| 05/31/2001 | WO2001037845A1 Treatment of heart rhythm disturbances with n6-substituted-5'-(n-substituted) carboxamidoadenosines |
| 05/31/2001 | WO2001037844A1 Immuno-active, anti-cancer and pharmacologically active polysaccharide compounds and pharmaceutical compositions containing the polysaccharide compounds |
| 05/31/2001 | WO2001037843A1 Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs |
| 05/31/2001 | WO2001037841A1 Pharmaceutical compositions comprising trimegestone |
| 05/31/2001 | WO2001037840A1 Methods for treating mild cognitive impairment |
| 05/31/2001 | WO2001037839A1 Pernasal preparation |
| 05/31/2001 | WO2001037838A1 Ophthalmic aqueous preparation |
| 05/31/2001 | WO2001037837A1 3,4-DIHYDRO-(1H)-QUINAZOLIN-2-ONES AND THEIR USE AS CSBP/p38 KINASE INHIBITORS |
| 05/31/2001 | WO2001037836A1 Diimino-piperazine derivatives for use as modulators of cell regulation |
| 05/31/2001 | WO2001037835A1 Novel compounds |
| 05/31/2001 | WO2001037834A1 Stable acid labile benzimidazole pharmaceutical compositions |
| 05/31/2001 | WO2001037833A1 Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl |
| 05/31/2001 | WO2001037832A2 Combination of riluzole and gabapentin and use thereof as medicine |
| 05/31/2001 | WO2001037831A1 PHARMACEUTICAL COMBINATION COMPRISING SEPARATE DOSAGE FORMS IN A COMPLIANCE PACKAGE OF AN INHIBITOR OF HMG CoA REDUCTASE AND FIBRIC ACID DERIVATIVE |
| 05/31/2001 | WO2001037830A1 Method for increasing the concentration of ascorbic acid in brain tissues of a subject |
| 05/31/2001 | WO2001037829A1 Composition comprising ozonized oils and/or other ozonized natural and/or synthetic products and their use in pharmaceutical, cosmetic, dietetic or food supplement compositions in human and veterinary medicine |
| 05/31/2001 | WO2001037828A1 Use of pleuromutilin derivatives for transdermal treatment of bacterial diseases |
| 05/31/2001 | WO2001037827A1 Therapeutic intervention to mimic the effect of caloric restriction |
| 05/31/2001 | WO2001037826A1 Npyy5 antagonists |
| 05/31/2001 | WO2001037825A1 Injectable preparation for controlling fish live comprising benzoyl urea derivatives |
| 05/31/2001 | WO2001037824A1 Use of 5ht3 agonists for relaxing the fundus |
| 05/31/2001 | WO2001037823A1 Substituted nitrobenzene derivatives as medicines and other useful uses thereof |
| 05/31/2001 | WO2001037820A2 Ionizable indolinone derivatives and their use as ptk ligands |
| 05/31/2001 | WO2001037819A2 Use of indirubine derivatives for making medicines |
| 05/31/2001 | WO2001037818A2 Medicament and combination of compatible medicaments |
| 05/31/2001 | WO2001037816A2 Coating of tablet cores |
| 05/31/2001 | WO2001037815A1 Osmotic dosage form comprising first and second |
| 05/31/2001 | WO2001037814A1 Bilayered buccal tablets comprising nicotine |
| 05/31/2001 | WO2001037813A2 Multilayer preparation for a controlled, pulsed release of active substances |
| 05/31/2001 | WO2001037812A2 Gastroretentive controlled release pharmaceutical dosage forms |
| 05/31/2001 | WO2001037808A1 Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| 05/31/2001 | WO2001037806A1 Composition and method for treatment of otitis media |
| 05/31/2001 | WO2001037805A1 Pharmaceutical formulations of salmeterol |
| 05/31/2001 | WO2001037785A2 Novel methods and compositions involving opioids and antagonists thereof |
| 05/31/2001 | WO2001037782A2 Method and composition for the treatment of scars |
| 05/31/2001 | WO2001037781A2 A stable aqueous dispersion of nutrients |
| 05/31/2001 | WO2001037770A1 Improved transdermal contraceptive delivery system and process |
| 05/31/2001 | WO2001037681A1 Phytosterol and phytostanol compositions |
| 05/31/2001 | WO2001037667A1 Combination of n-phenyl-n'-benzoyl urea derivative and nectin compounds for parasite control |
| 05/31/2001 | WO2001009103A3 Imidazole antiproliferative agents |
| 05/31/2001 | WO2001005411A8 Compositions addressing inflammation and/or degenerative disorders |
| 05/31/2001 | WO2001003683A3 Cardioactive composition comprising l-carnitine and its derivatives and crataegus extracts |
| 05/31/2001 | WO2000073307A3 Substituted 8-phenylxanthines useful as antagonists of a2b adenosine receptors |
| 05/31/2001 | WO2000072806A3 Sunscreen composition containing sol-gel microcapsules |
| 05/31/2001 | WO2000071140A3 Methods and compositions for modulating immune response and for the treatment of inflammatory disease |
| 05/31/2001 | WO2000069472A3 Enzyme-activated anti-tumor prodrug compounds |
| 05/31/2001 | WO2000066708A3 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 05/31/2001 | WO2000066593A3 Novel spirocyclic compounds, method for the production thereof and their use for treating hyperproliferative diseases |
| 05/31/2001 | WO2000066098A3 Vitamin d derivatives for the treatment of systemic lupus erythematosus |
| 05/31/2001 | WO2000064414A3 Solid pharmaceutical formulations of acid-sensitive proton-pump blockers |
| 05/31/2001 | WO2000063222A3 Novel ribose-substituted aromatic amides, method for the production and use thereof as medicaments |
| 05/31/2001 | WO2000061754A3 Human proteins and polynucleotides encoding them |
| 05/31/2001 | WO2000057864A3 Cyclic glycerophosphates and analogs thereof |
| 05/31/2001 | WO2000047194A9 METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR |
| 05/31/2001 | WO2000042071A3 Compounds and methods to inhibit or augment an inflammatory response |
| 05/31/2001 | WO2000032196A3 Inhibitors of multidrug transporters |
| 05/31/2001 | WO2000010507A3 Use of melanin for inhibition of angiogenesis and macular degeneration |
| 05/31/2001 | WO2000009512A3 Bipyridine manganese complexes |
| 05/31/2001 | WO2000004187A3 Methods and kits for diagnosing and determination of the predisposition of diseases |
| 05/31/2001 | WO1999064041A9 Multibinding agents that modulate nmda receptors |
| 05/31/2001 | WO1999032454A9 Nitrogen containing heteroaromatics with ortho-substituted p1's as factor xa inhibitors |
| 05/31/2001 | WO1999024394A9 Compounds for the antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
| 05/31/2001 | WO1998027972A8 Anti-amyloidogenic agents |
| 05/31/2001 | US20010002421 Exposing intracellular pathogen in cell or animal culture to the test agent in the absence of cyclohexamine and determining the presence/absence of the pathogen by determining the presence/absence of the gene; amplification |
| 05/31/2001 | US20010002407 Isolated cherry extract containing anthocyanins, bioflavonoids and phenolics as antiinflammatory and antiarthritic agents; food additives; tablets; enzyme inhibitors |
| 05/31/2001 | US20010002406 Administering an anesthetic to the area where capsaicin or an analogue are administered transdermally for neuropathic pain; kits containing two patches; desensitization of C fibers; peripheral neuropathy |
| 05/31/2001 | US20010002405 Topical and oral delivery of arginine to cause beneficial effects |
| 05/31/2001 | US20010002404 Treating a noncentral nervous system by administering a covalent conjugate of a C8-26, unbranched, naturally occurring fatty acid and a drug, provided the drug is not an adenosine receptor agonist/antagonist; anticarcinogenics |
| 05/31/2001 | US20010002403 N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions |
| 05/31/2001 | US20010002401 Establishing the status of the mammal as presently or prospectively being in early stages of degeneration of articular cartilage or subchondral bone in one or more joinsts, administering a xanthine chondroprotective compound |
| 05/31/2001 | US20010002400 Administering an antifungal agent |
| 05/31/2001 | US20010002399 Use of low dose amount of spironolactone for treatment of cardiovascular disease |
| 05/31/2001 | US20010002398 (6S)- or 10 (6R,S)- tetrahydrofolic acid is crystallized in a polar medium with pH of 3.5 or greater and have a purity 98% |
| 05/31/2001 | US20010002397 24-Hydroxyvitamin D, analogs and uses thereof |
| 05/31/2001 | US20010002396 Comprising a vitamin D analog and a retinoid, vitamin D analog is capable of binding a vitamin D receptor and the retinoid consisting of a compound capable of binding a retinoic acid receptor; treats abnormal cell proliferation |
| 05/31/2001 | US20010002395 Orally administering to the mammal for inhibiting bone resorption an effective amount of biphosphonate as an unit dosage according to a continuous schedule having dosing interval between once-weekly or twice-weekly etc. |
| 05/31/2001 | US20010002394 Use of a polypeptide containing specific amino acid sequence or analogue or derivatives as a drug for the treatment of diabetes together with an oral hypoglycemic agent |
| 05/31/2001 | US20010002393 Administering to a patient suffering from leiomyoma (fibroid)of uterus an effective dose of an agent which specifically inhibit metalloproteinase selected from stromelysin-2, stromelysin-3 and matrilysin |
| 05/31/2001 | US20010002391 Administering to the mammal for ischmeic treatment an effective amount of an necrosis factor(NF)- kappa B activation inhibitor selected from the group consisting of proteasome inhibitor, ubiquitin pathwaty inhibitors |
| 05/31/2001 | US20010002290 Comprising allantoin and at least one anionic or nonionic emulsifier that is substantially hydrophilic and is soluble in water; skin protectant |
| 05/31/2001 | US20010002264 Citrus peel extract as inhibitor of fatty streak formation on the arterial wall |
| 05/31/2001 | US20010002260 Extracts of zanthoxylum bungeanum, and pharmaceutical and cosmetic formulations containing same |
| 05/31/2001 | US20010002259 Applying a transdermal delivery system containing analgesicbuprenorphine sufficient to maintain an adequate onto the skin of the patient and maintaining the relative release rate to provide a specific plasma concentration |
| 05/31/2001 | US20010002257 Amino acid or oligopeptide together with tannin rich plant extract selected from rathania, tea, cinnamon, willow or witch hazel; useful for treating acne, antiaging agent of skin or treating scalp |
| 05/31/2001 | US20010002254 A developer for oxidative dyeing of hair containing a primary thickening agents of copolymer of acrylic or mathacrylic acid and acrylic or methacrylic ester or mixtures, a nonionic surfactant, hydrogen peroxide and water |
| 05/31/2001 | DE19957710A1 Treating female type androgenetic or diffuse alopecia by topical administration of melatonin, causing e.g. reduction of telogen rate and increase of anagen rate, hair diameter and tensile strength |
| 05/31/2001 | DE19957156A1 New amino and fluoro substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocine derivatives useful in treatment of e.g. arrythmias, spasms, ischaemia, pain and neurodegenerative disorders |
| 05/31/2001 | DE19956848A1 Curcumin-Formulierungen Curcumin formulations |
| 05/31/2001 | DE19956791A1 New 2-heterocyclyl-4-arylsulfonyl-5-amino-oxazole derivatives useful in treatment of central nervous system disorders and as pesticides |
| 05/31/2001 | DE19954788A1 Inhibition of epithelial cell adhesion in vivo or in vitro using the calcium channel blocker mibefradil, especially useful for preventing post-cataract formation after cataract surgery |